Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

NCT04493203 is registered in ClinicalTrials.gov with Yana Najjar as lead sponsor.

NCT NCT04493203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04493203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Lead sponsor
Yana Najjar
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2020
Completion date
April 12, 2025
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, unresectable melanoma